购物车
- 全部删除
- 您的购物车当前为空
Cevoglitazar (LBM-642) 是一种 PPARɑ 激动剂和 PPARγ激动剂。Cevoglitazar 能有效减少肥胖小鼠和猴的食物摄入量和体重。
为众多的药物研发团队赋能,
让新药发现更简单!
Cevoglitazar (LBM-642) 是一种 PPARɑ 激动剂和 PPARγ激动剂。Cevoglitazar 能有效减少肥胖小鼠和猴的食物摄入量和体重。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 760 | 现货 | |
5 mg | ¥ 1,830 | 现货 | |
10 mg | ¥ 2,730 | 现货 | |
25 mg | ¥ 4,570 | 现货 | |
50 mg | ¥ 6,490 | 现货 | |
100 mg | ¥ 8,890 | 现货 | |
500 mg | ¥ 17,800 | 现货 |
产品描述 | Cevoglitazar (LBM-642) is a PPARɑ agonist and PPARγ agonist. Cevoglitazar potently reduces food intake and body weight in obese mice and cynomolgus monkeys. |
体内活性 | Cevoglitazar (0.5 mg/kg; 7 d) plasma levels of glucose and insulin were normalized.[1] Cevoglitazar (50 and 500 mg/kg; obese and insulin-resistant cynomolgus monkeys; 4 weeks) lowered food intake and body weight in a dose-dependent manner. In these animals, cevoglitazar also reduced fasting plasma insulin and, at the highest dose, reduced hemoglobin A1c levels by 0.4%.[1] Cevoglitazar (5 mg/kg) reduced BW gain and adiposity, independent of food intake. In the muscle, cevoglitazar improves the lipid profile via both PPARalpha- and PPARgamma-mediated mechanisms, and cevoglitazar reduced hepatic lipid concentration below baseline levels (p < 0.05). Metabolic profiling showed that in the liver, cevoglitazar functions largely through PPARalpha agonism resulting in increased beta-oxidation. Cevoglitazar only induced small changes to the lipid composition of visceral fat.[2] |
别名 | LBM-642, LBM 642, LBM642 |
分子量 | 558.53 |
分子式 | C27H21F3N2O6S |
CAS No. | 839673-52-8 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 50 mg/mL (89.52 mM) | ||||||||||||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||||||||||||
DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.